News >

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases

Danielle Ternyila
Published: Thursday, May 23, 2019

Myung-Ju Ahn, MD
Myung-Ju Ahn, MD
Osimertinib (Tagrisso) at a once-daily dose of 80 mg demonstrated similar signs of activity, as well as a clinically meaningful benefit in patients with EGFR T790M–positive advanced non–small cell lung cancer (NSCLC) who had radiographically detected leptomeningeal metastases (LM) compared with the 160-mg dose observed in the AURA LM trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Community Practice Connections™: 3rd Annual School of Gastrointestinal Oncology® (SOGO®)Jun 29, 20191.5
Publication Bottom Border
Border Publication